Biomea Fusion reports initial data from first two T1D patients dosed with BMF-219; C-peptide increased

Biomea Fusion, Inc.

Patient 1 (200 mg): fasting C-peptide +57% at week 4, +80% at week 8; MMTT C-peptide index AUC +12% and +40%.
Patient 2 (100 mg): fasting C-peptide +16% at week 4; MMTT C-peptide index AUC +30%; reduced daily insulin usage.
BMF-219 well tolerated in both patients; no safety signals reported.
Open-label portion of COVALENT-112 (n=40) with 12-week dosing data expected in 2024.
First type 2 diabetes patient in COVALENT-111 discontinued metformin after week 40 with improved glycemic control.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.